01.07.2024 06:50:04
|
EQS-News: Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
EQS-News: Formycon AG
/ Key word(s): Regulatory Approval
Press Release // July 01, 2024 Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2) Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA") approved FYB203/AHZANTIVE® (aflibercept-mrbb), a biosimilar to Eylea®, on June 28, 2024. Dr. Stefan Glombitza, CEO of Formycon AG, commented: “The FDA approval of FYB203/AHZANTIVE® is another key milestone on our way to becoming the leading pure-play biosimilar developer. It highlights the expertise and experience of our team. With the Eylea® biosimilar FYB203/AHZANTIVE® and our already approved Lucentis®3) biosimilar FYB201, we have achieved an outstanding position in ophthalmic biosimilar therapies. We are thus improving healthcare for patients with retinal diseases by offering effective, safe and, above all, affordable treatment options.” FYB203/AHZANTIVE® obtained FDA approval for the treatment of patients with Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Macular Edema following Retinal Vein Occlusion (RVO). The active ingredient inhibits the vascular endothelial growth factor (“VEGF”), which is responsible for the excessive formation of blood vessels in the retina. In 2023, Eylea® reached global sales of around US$ 9 billion4), confirming its status as the currently best-selling drug in the field of anti-VEGF therapies. The FDA approval for FYB203/AHZANTIVE® is based on a thorough evaluation of our comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. FYB203/AHZANTIVE® demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Eylea® in patients with Age-Related Neovascular (wet) Macular Degeneration (nAMD). In addition, a marketing authorization application for FYB203 was submitted to the European Medicines Agency ("EMA") at the end of 2023. A decision by EMA is expected by early 2025 at the latest. 1) AHZANTIVE® is a registered trademark of Klinge Biopharma GmbH
About Formycon: About Biosimilars: Contact:
Disclaimer:
01.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Formycon AG |
Fraunhoferstraße 15 | |
82152 Planegg-Martinsried | |
Germany | |
Phone: | 089 864667 100 |
Fax: | 089 864667 110 |
Internet: | www.formycon.com |
ISIN: | DE000A1EWVY8 |
WKN: | A1EWVY |
Indices: | Scale 30 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1936215 |
End of News | EQS News Service |
|
1936215 01.07.2024 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Formycon AGmehr Nachrichten
28.02.25 |
Handel in Frankfurt: TecDAX zeigt sich letztendlich leichter (finanzen.at) | |
28.02.25 |
EQS-AFR: Formycon AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG (EQS Group) | |
28.02.25 |
EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (EQS Group) | |
27.02.25 |
TecDAX-Wert Formycon-Aktie: So viel hätten Anleger an einem Formycon-Investment von vor 10 Jahren verdient (finanzen.at) | |
27.02.25 |
Börse Frankfurt: TecDAX zum Start des Donnerstagshandels mit Abgaben (finanzen.at) | |
27.02.25 |
XETRA-Handel SDAX startet in der Verlustzone (finanzen.at) | |
25.02.25 |
Angespannte Stimmung in Frankfurt: TecDAX liegt am Mittag im Minus (finanzen.at) | |
25.02.25 |
SDAX aktuell: SDAX am Mittag in Rot (finanzen.at) |
Analysen zu Formycon AGmehr Analysen
24.02.25 | Formycon Buy | Warburg Research | |
20.02.25 | Formycon Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
18.02.25 | Formycon Buy | Hauck Aufhäuser Lampe Privatbank AG | |
18.02.25 | Formycon Buy | Warburg Research | |
18.02.25 | Formycon Outperform | RBC Capital Markets |
Aktien in diesem Artikel
Formycon AG | 26,60 | -1,85% |
|